Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.

Acute disseminated encephalomyelitis (ADEM) Antibodies Brainstem encephalitis Cerebrospinal fluid Children Encephalomyelitis Lumbar puncture MOG antibody-associated disease (MOGAD) Multiple sclerosis (MS) Myelin oligodendrocyte glycoprotein (MOG) NMO spectrum disorders Neuromyelitis optica (Devic syndrome) Oligoclonal bands Optic neuritis Transverse myelitis

Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
03 Sep 2020
Historique:
received: 07 11 2019
accepted: 23 04 2020
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 22 7 2021
Statut: epublish

Résumé

New-generation, cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD). To describe systematically the CSF profile in children with MOG-EM. Cytological and biochemical findings (including white cell counts [WCC] and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgM/IgA fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster [MRZ] reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 108 lumbar punctures in 80 pediatric patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively. Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in 89% of samples (N = 96), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 29). If present at all, intrathecal IgG synthesis was low, often transient and mostly restricted to acute attacks. Intrathecal IgM synthesis was present in 21% and exclusively detectable during acute attacks. CSF WCC were elevated in 54% of samples (median 40 cells/μl; range 6-256; mostly lymphocytes and monocytes; > 100/μl in 11%). Neutrophils were present in 71% of samples; eosinophils, activated lymphocytes, and plasma cells were seen only rarely (all < 7%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 46% of all samples (N = 79) and at least once in 48% of all patients (N = 67) tested. CSF alterations were significantly more frequent and/or more pronounced in patients with acute spinal cord or brain disease than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesions load (measured in vertebral segments) in patients with acute myelitis (p = 0.0099). An analysis of pooled data from the pediatric and the adult cohort showed a significant relationship of QAlb (p < 0.0005), CST TP (p < 0.0001), and CSF L-lactate (p < 0.0003) during acute attacks with age. MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS. With regard to most parameters, no marked differences between the pediatric cohort and the adult cohort analyzed in Part 1 were noted. Our findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.

Sections du résumé

BACKGROUND BACKGROUND
New-generation, cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).
OBJECTIVE OBJECTIVE
To describe systematically the CSF profile in children with MOG-EM.
MATERIAL AND METHODS METHODS
Cytological and biochemical findings (including white cell counts [WCC] and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgM/IgA fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster [MRZ] reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 108 lumbar punctures in 80 pediatric patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively.
RESULTS RESULTS
Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in 89% of samples (N = 96), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 29). If present at all, intrathecal IgG synthesis was low, often transient and mostly restricted to acute attacks. Intrathecal IgM synthesis was present in 21% and exclusively detectable during acute attacks. CSF WCC were elevated in 54% of samples (median 40 cells/μl; range 6-256; mostly lymphocytes and monocytes; > 100/μl in 11%). Neutrophils were present in 71% of samples; eosinophils, activated lymphocytes, and plasma cells were seen only rarely (all < 7%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 46% of all samples (N = 79) and at least once in 48% of all patients (N = 67) tested. CSF alterations were significantly more frequent and/or more pronounced in patients with acute spinal cord or brain disease than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesions load (measured in vertebral segments) in patients with acute myelitis (p = 0.0099). An analysis of pooled data from the pediatric and the adult cohort showed a significant relationship of QAlb (p < 0.0005), CST TP (p < 0.0001), and CSF L-lactate (p < 0.0003) during acute attacks with age.
CONCLUSION CONCLUSIONS
MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS. With regard to most parameters, no marked differences between the pediatric cohort and the adult cohort analyzed in Part 1 were noted. Our findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.

Identifiants

pubmed: 32883358
doi: 10.1186/s12974-020-01825-1
pii: 10.1186/s12974-020-01825-1
pmc: PMC7470445
doi:

Substances chimiques

Autoantibodies 0
Immunoglobulins 0
Myelin-Oligodendrocyte Glycoprotein 0
Oligoclonal Bands 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

262

Subventions

Organisme : Dietmar Hopp Stiftung
ID : N/A
Organisme : Merck Serono Germany
ID : N/A
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : N/A
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : N/A
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : N/A
Organisme : Deutsche Forschungsgemeinschaft (DFG Exc 257)
ID : N/A
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : 01GM1908A
Organisme : ERA-net
ID : LE3064/2-1
Organisme : Jubilaeumsfonds of the Austrian National Bank
ID : 14158 and 15918

Références

Neurology. 2004 Dec 28;63(12):2363-70
pubmed: 15623701
Neurology. 1999 Sep 22;53(5):1107-14
pubmed: 10496275
J Neuroinflammation. 2013 Jan 15;10:8
pubmed: 23320783
Mult Scler. 2009 Dec;15(12):1466-80
pubmed: 19995844
Ann Neurol. 2006 Mar;59(3):566-9
pubmed: 16453327
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
Dtsch Med Wochenschr. 1979 Apr 13;104(15):553-7
pubmed: 436627
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
J Neurol Sci. 1994 Apr;122(2):189-203
pubmed: 8021703
J Neurol Sci. 2019 Dec 15;407:116396
pubmed: 31726278
Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083
pubmed: 29623106
J Neuroinflammation. 2018 Jan 18;15(1):22
pubmed: 29347989
Clin Chem Lab Med. 2010 May;48(5):659-63
pubmed: 20184532
Neurology. 2011 Aug 9;77(6):580-8
pubmed: 21795651
Brain. 2008 Nov;131(Pt 11):3072-80
pubmed: 18945724
J Neurol. 2017 Mar;264(3):453-466
pubmed: 28005176
J Exp Med. 1986 Jan 1;163(1):41-53
pubmed: 3941297
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
Acta Neurol Scand. 1988 Jul;78(1):6-9
pubmed: 3176884
Arch Pediatr Adolesc Med. 2000 Aug;154(8):827-31
pubmed: 10922281
Clin Exp Immunol. 2014 May;176(2):149-64
pubmed: 24666204
J Gen Physiol. 1992 Aug;100(2):341-67
pubmed: 1402785
Med Hypotheses. 2013 Dec;81(6):1090-5
pubmed: 24182872
Neurosci Lett. 1988 Apr 12;86(3):296-300
pubmed: 3380321
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Arch Neurol. 1967 May;16(5):492-6
pubmed: 6022530
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Clin Chem. 2012 May;58(5):854-68
pubmed: 22371482
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
Eur J Paediatr Neurol. 2017 Jul;21(4):654-660
pubmed: 28461111
Arch Neurol. 2007 Dec;64(12):1802; author reply 1802-3
pubmed: 18071052
Neurology. 2003 Jul 8;61(1):125-8
pubmed: 12847174
Curr Opin Neurol. 2017 Jun;30(3):295-301
pubmed: 28248700
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
Am J Med. 1995 Aug;99(2):153-63
pubmed: 7625420
J Exp Med. 2008 Oct 27;205(11):2473-81
pubmed: 18838545
Mult Scler. 2016 Oct;22(12):1541-1549
pubmed: 26869529
Arch Intern Med. 1983 Jan;143(1):85-7
pubmed: 6849611
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Glia. 1988;1(6):366-70
pubmed: 2976396
J Neuroinflammation. 2018 Mar 19;15(1):88
pubmed: 29554927
Nat Rev Neurol. 2019 Feb;15(2):89-102
pubmed: 30559466
Mult Scler. 2015 Oct;21(12):1513-20
pubmed: 25662345
J Neuroinflammation. 2017 Aug 29;14(1):171
pubmed: 28851393
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
Arthritis Rheum. 2010 Apr;62(4):1198-200
pubmed: 20131265
Neurology. 2017 Aug 29;89(9):900-908
pubmed: 28768844
J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1134-6
pubmed: 18270237
Arch Neurol. 2007 Jun;64(6):899-901
pubmed: 17562942
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
Neurology. 2012 Sep 18;79(12):1273-7
pubmed: 22914827
J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
J Neurol. 2014 Jan;261(1):1-16
pubmed: 24272588
Cerebrospinal Fluid Res. 2005 Jun 27;2:3
pubmed: 15982411
J Cereb Blood Flow Metab. 1989 Jun;9(3):381-7
pubmed: 2497112
Arch Neurol. 2007 Jun;64(6):901-3
pubmed: 17562943
Mult Scler. 1998 Jun;4(3):111-7
pubmed: 9762657
Autoimmun Rev. 2016 Apr;15(4):307-24
pubmed: 26708342
Neurology. 2006 May 23;66(10):1485-9
pubmed: 16717206
J Neuroinflammation. 2019 Dec 28;16(1):280
pubmed: 31883522
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):897-905
pubmed: 26645082
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):446-51
pubmed: 9343121
Arch Neurol. 2007 Jun;64(6):906
pubmed: 17562945
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
Medicine (Baltimore). 2004 Sep;83(5):280-91
pubmed: 15342972
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Clin Chim Acta. 1975 Dec 15;65(3):319-29
pubmed: 1204222
Arch Neurol. 2010 Oct;67(10):1201-8
pubmed: 20937947
Mult Scler. 2016 Dec;22(14):1821-1829
pubmed: 26869530
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
J Neurol Sci. 2009 May 15;280(1-2):98-100
pubmed: 19041103
J Neurol Sci. 2011 Jul 15;306(1-2):82-90
pubmed: 21550068
Lancet Neurol. 2016 Mar;15(3):317-31
pubmed: 26724102
J Neurosci. 2006 Mar 22;26(12):3220-8
pubmed: 16554473
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2010 Sep 08;7:52
pubmed: 20825655
J Neuroinflammation. 2019 Feb 28;16(1):51
pubmed: 30819213
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
Mult Scler. 2011 Sep;17(9):1067-73
pubmed: 21543553
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513

Auteurs

Sven Jarius (S)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.

Christian Lechner (C)

Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.

Eva M Wendel (EM)

Department of Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany.

Matthias Baumann (M)

Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.

Markus Breu (M)

Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Mareike Schimmel (M)

Division of Pediatric Neurology, Children's Hospital, Medical University of Augsburg, Augsburg, Germany.

Michael Karenfort (M)

Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine-University, Düsseldorf, Germany.

Adela Della Marina (AD)

Department of Neuropediatrics, Developmental Neurology and Social Pediatrics, Children's Hospital, University of Duisburg-Essen, Duisburg, Germany.

Andreas Merkenschlager (A)

Division of Pediatric Neurology, University Hospital for Children and Adolescents, Leipzig, Germany.

Charlotte Thiels (C)

Department of Neuropediatrics, University Children's Hospital, Ruhr-University Bochum, Bochum, Germany.

Astrid Blaschek (A)

Department of Pediatric Neurology and Developmental Medicine, Dr. von Hauner Children's Hospital, University of Munich, Munich, Germany.

Michela Salandin (M)

Department of Pediatrics, Bozen Hospital, Bozen, Italy.

Steffen Leiz (S)

Department of Pediatrics, Division of Pediatric Neurology, Klinikum Dritter Orden, Munich, Germany.

Frank Leypoldt (F)

Neuroimmunology, Institute of Clinical Chemistry and Department of Neurology, Christian-Albrechts-University Kiel and Medical University Hospital Schleswig-Holstein, Kiel, Germany.

Alexander Pschibul (A)

Department of Neuropediatrics and Muscle Disorders, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Annette Hackenberg (A)

Division of Pediatric Neurology, University Children's Hospital Zurich, Zurich, Switzerland.

Andreas Hahn (A)

Department of Pediatric Neurology, University Children's Hospital Giessen, Giessen, Germany.

Steffen Syrbe (S)

Division of Child Neurology and Inherited Metabolic Diseases, Department of General Pediatrics, Center for Child and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Jurgis Strautmanis (J)

Department of Neurology, Children's Clinical University Hospital, Riga, Latvia.

Martin Häusler (M)

Department of Pediatrics, Division of Neuropediatrics and Social Pediatrics, Medical University RWTH Aachen, Aachen, Germany.

Peter Krieg (P)

Department of Pediatrics, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.

Astrid Eisenkölbl (A)

Department of Pediatrics, Women's and Children's Hospital, Linz, Austria.

Johannes Stoffels (J)

Department of Pediatric Neurology, Children's Hospital Neuburg, Neuburg, Germany.

Matthias Eckenweiler (M)

Department of Neuropediatrics and Muscle Disorders, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Ilya Ayzenberg (I)

Department of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.

Jürgen Haas (J)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Romana Höftberger (R)

Institute of Neurology, Medical University of Vienna, Vienna, Austria.

Ingo Kleiter (I)

Department of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany.

Mirjam Korporal-Kuhnke (M)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Marius Ringelstein (M)

Department of Neurology, Medical Faculty, Heinrich Heine University Dusseldorf, Düsseldorf, Germany.
Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Dusseldorf, Düsseldorf, Germany.

Klemens Ruprecht (K)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Nadja Siebert (N)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité Universitätsmedizin Berlin, Berlin, Germany.

Kathrin Schanda (K)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Orhan Aktas (O)

Department of Pediatric Neurology, Children's Hospital Neuburg, Neuburg, Germany.

Friedemann Paul (F)

NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité Universitätsmedizin Berlin, Berlin, Germany.

Markus Reindl (M)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Brigitte Wildemann (B)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Kevin Rostásy (K)

Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Datteln, Germany. k.rostasy@kinderklinik-datteln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH